Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

MOSASPRAY DIN 02455870

Status: Cancelled Post Market
Holder: SANDOZ CANADA INCORPORATED
Molecule: MOMETASONE FUROATE (MOMETASONE FUROATE MONOHYDRATE)

Health Canada record

Active ingredient(s)MOMETASONE FUROATE (MOMETASONE FUROATE MONOHYDRATE) 50 MCG
Dosage formSpray (Metered-Dose)
RouteNasal
ScheduleNON-PRESCRIPTION DRUGS
ClassHuman
ATCR01AD09 MOMETASONE
Original market date17-Jun-2016
Current status date20-Jul-2020
SourceHealth Canada DPD

Establishment licence of the holder

Sandoz Canada Incorporated — licence 101370, currently licensed, last inspection rating C (2025-02-25).

No Canadian shortage report is currently matched to this DIN.

Other Canadian products containing MOMETASONE FUROATE (MOMETASONE FUROATE MONOHYDRATE)

DINProductCompanyFormStrengthStatus
02519127MOMETASONESANIS HEALTH INCSpray (Metered-Dose)MOMETASONE FUROATE (MOMETASONE FUROATE MONOHYDRATE) 50 MCGMarketed
02551756MOMETASONESIVEM PHARMACEUTICALS ULCSpray (Metered-Dose)MOMETASONE FUROATE (MOMETASONE FUROATE MONOHYDRATE) 50 MCGMarketed
02449811SANDOZ MOMETASONESANDOZ CANADA INCORPORATEDSpray (Metered-Dose)MOMETASONE FUROATE (MOMETASONE FUROATE MONOHYDRATE) 50 MCGMarketed

Notices of Compliance

NOCDateSubmissionReason
181882016-06-17Abbreviated New Drug Submission (ANDS)
Request a quote for MOSASPRAY

How to read a Canadian DIN record